Answers are grounded in this paper and cite their sources.
INTRODUCTION: Pembrolizumab plus lenvatinib is an established post-platinum option for advanced or recurrent endometrial cancer, particularly mismatch repair-proficient (pMMR) disease, in which single-agent programmed cell death protein 1 (PD-1) blockade has limited activity. AREAS COVERED: This narrative review critically evaluates the pharmacology, pharmacokinetics, metabolism, drug-interaction potential, efficacy and safety of pembrolizumab plus lenvatinib. Evidence from KEYNOTE-146, KEYNOTE-775, its 5-year analysis, ENGOT-en9/LEAP-001 and contemporary real-world cohorts was identified through searches of PubMed/MEDLINE, Embase, Scopus, Web of Science and the Cochrane Library from database inception to 14 August 2026, supplemented by ClinicalTrials.gov, regulatory documents and major congress proceedings. EXPERT OPINION: Pembrolizumab plus lenvatinib improves survival after platinum therapy in immune checkpoint inhibitor-naive advanced endometrial cancer, but substantial toxicity requires proactive monitoring and frequent lenvatinib dose modification. Its therapeutic position is being redefined by first-line chemoimmunotherapy and the negative ENGOT-en9/LEAP-001 trial, while post-immunotherapy efficacy, predictive biomarkers and prospectively validated dosing strategies remain key research priorities.
No takes yet. Share an insight, caveat, or question.
Ferrero et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: